Materials

Our expertise in bone, cartilage, teeth and complex tissue materials research includes:

  • biomaterial development and characterisation including both traditional dental materials and scaffolds/constructs for tissue engineering
  • interactions between biomaterials and cells in vitro and in vivo
  • comparison of different stem cell populations and the way they respond to environmental triggers
  • non-viral gene therapy for tissue engineering
  • development of new biomaterials and innovative manufacturing process
  • stem cell biology and cell based regenerative therapies

The University of Leeds has a dedicated Dental Clinical Research Facility supporting research advancements into rapid translation and adoption.

Targeted drug delivery

The University of Leeds also brings together engineers, physicists, chemists and cancer patients to work on techniques for targeted drug delivery. Examples of this capability include using small gas filled bubbles (microbubbles) and the use of ultrasound to deliver anti-cancer drugs to specific areas in the body. The University of Leeds hosts the Leeds Microbubble Consortium which brings these multi-disciplinary teams together to apply these technological advancements to deliver personalised treatments to patients.

For more information on our work in this area please visit Leeds Microbubble Consortium and the Ultrasound and Instrumentation Group.

Devices for MSCs

Researchers at the University of Leeds have renowned expertise in developing novel quality-control tools for the therapeutic use of minimally-manipulated, bone-derived mesenchymal stem cells (MSCs). These can be used for bone repair applications including acute fractures, segmental bone defects, fracture non-unions and also to treat osteoarthritis.

Improved management and treatment of osteoarthritis focuses on:

  • earlier diagnosis
  • improved non-surgical interventions
  • earlier and tissue sparing interventions including acellular scaffolds
  • longer lasting joint replacements
  • better targeting of interventions to meet stratified patient need
  • greater precision and targeting in the design and delivery of devices
  • improved reliability of treatments 

Find out more about our work with MSCs